Program
praliciguat
Also written as “IW-1973”, “Praliciguat (Part A)” and “Praliciguat (Part B)”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Glomerulosclerosis, Focal Segmental · Heart Failure, led by 2 companies.
Drug pagePraliciguat: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ironwood Pharmaceuticalsits history only | 50 open or running | phase 2since Sep 15, 2016 | Oct 29, 2015 | none ahead |
| Akebia Therapeutics | 31 open or running | phase 2since Jul 12, 2017 | Jul 12, 2017 | Jun 2027phase 2 · NCT07268638 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Akebia Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2016Named praliciguatINNProposed as its International Nonproprietary Name in WHO's List 116 · before, IW-1973
- Jul 12, 2017First study: phase 2 study in Type 2 Diabetes Mellitus With Diabetic NephropathyFirst studyNCT03217591 · 156 enrolled · United States
- Aug 16, 2017Phase 2 study in Heart FailureNCT03254485 · 196 enrolled · United States, Canada
- Nov 26, 2025Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT07268638 · 60 planned · United States
Ahead
- Jun 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT07268638
TargetBeta
“Soluble guanylate cyclase activator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Nitroglycerinrule | mediquest-therapeutics | phase 4 | 14 |
| ataciguatrule | Sanofi | phase 3 | 3 |
Studies
All 3 Akebia Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07268638Glomerulosclerosis, Focal Segmental · United States | 2 | Recruiting | Jun 2027 | 60 |
| NCT03254485Heart Failure · United States, Canada | 2 | Completed | Aug 19, 2019 | 196 |
| NCT03217591Type 2 Diabetes Mellitus With Diabetic Nephropathy · United States | 2 | Completed | Aug 20, 2019 | 156 |
How it is read
Names in the registry
- “IW-1973”, 7 entries
- “Praliciguat (Part A)”, 1 entry
- “Praliciguat (Part B)”, 1 entry
- “[14C]-praliciguat”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Glomerulosclerosis, Focal Segmental, 1 study
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.